Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mesoblast Ltd (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.91 - $22.00
Previous CloseN/A
Volume155.35K
Average Volume (3M)324.46K
Market Cap
$2.22B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 27, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding127,052,720
10 Day Avg. Volume203,526
30 Day Avg. Volume324,461
Standard Deviation0.36
R-Squared0.24
Alpha0.00888
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)333.33
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$27.00Price Target Upside64.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityMesoblast has sufficient inventory to support multiple years of sales and is targeting high-volume centers, positioning Ryoncil for a substantial market opportunity.
Regulatory ApprovalRyoncil gains approval in the US for pediatric steroid refractory acute graft vs host disease, marking a significant milestone for Mesoblast and validating FDA's supportive stance on cell therapy.
Bears Say
Regulatory RiskThe FDA's decision to reverse course and determine that the existing data appeared sufficient to file without an additional study led MESO shares to rebound and rise approximately 180% YTD.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.42% Other Institutional Investors
98.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MESO FAQ
What was Mesoblast Ltd’s price range in the past 12 months?
Mesoblast Ltd lowest stock price was $1.91 and its highest was $22.00 in the past 12 months.
What is Mesoblast Ltd’s market cap?
Mesoblast Ltd’s market cap is $2.22B.
When is Mesoblast Ltd’s upcoming earnings report date?
Mesoblast Ltd’s upcoming earnings report date is Aug 27, 2025 which is in 186 days.
How were Mesoblast Ltd’s earnings last quarter?
Currently, no data Available
Is Mesoblast Ltd overvalued?
According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued.
Does Mesoblast Ltd pay dividends?
Mesoblast Ltd does not currently pay dividends.
What is Mesoblast Ltd’s EPS estimate?
Mesoblast Ltd’s EPS estimate is -0.28.
How many shares outstanding does Mesoblast Ltd have?
Mesoblast Ltd has 127,052,720 shares outstanding.
What happened to Mesoblast Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mesoblast Ltd?
Currently, no hedge funds are holding shares in MESO
---
Mesoblast Stock Smart Score
Company Description
Mesoblast Ltd
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
---
MESO Stock 12 Month Forecast
Average Price Target
$27.00
▲(64.94% Upside)
Technical Analysis
Best Analysts Covering MESO
1 Year
1 Year Success Rate
3/7 ratings generated profit
1 Year Average Return
+32.97%
reiterated a buy rating 16 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +32.97% per trade.
---